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ttps://doi.org/10.1016/j.ajpath.2020.02.012Hyaluronidase (HYAL)-2 is a weak, acid-active, hyaluronan-degrading enzyme broadly expressed in
somatic tissues. Aberrant HYAL2 expression is implicated in diverse pathology. However, a significant
proportion of HYAL2 is enzymatically inactive; thus the mechanisms through which HYAL2 dysregulation
influences pathobiology are unclear. Recently, nonenzymatic HYAL2 functions have been described, and
nuclear HYAL2 has been shown to influence mRNA splicing to prevent myofibroblast differentiation.
Myofibroblasts drive fibrosis, thereby promoting progressive tissue damage and leading to multi-
morbidity. This study identifies a novel HYAL2 cytoplasmic function in myofibroblasts that is unrelated
to its enzymatic activity. In fibroblasts and myofibroblasts, HYAL2 interacts with the GTPase-signaling
small molecule ras homolog family member A (RhoA). Transforming growth factor beta 1edriven
fibroblast-to-myofibroblast differentiation promotes HYAL2 cytoplasmic relocalization to bind to the
actin cytoskeleton. Cytoskeletal-bound HYAL2 functions as a key regulator of downstream RhoA
signaling and influences profibrotic myofibroblast functions, including myosin light-chain kinase
emediated myofibroblast contractility, myofibroblast migration, myofibroblast collagen/fibronectin
deposition, as well as connective tissue growth factor and matrix metalloproteinase-2 expression. These
data demonstrate that, in certain biological contexts, the nonenzymatic effects of HYAL2 are crucial in
orchestrating RhoA signaling and downstream pathways that are important for full profibrotic myofi-
broblast functionality. In conjunction with previous data demonstrating the influence of HYAL2 on RNA
splicing, these findings begin to explain the broad biological effects of HYAL2. (Am J Pathol 2020, 190:
1236e1255; https://doi.org/10.1016/j.ajpath.2020.02.012)Supported by the United Kingdom Medical Research Council grant ID
MR/K010328/1 (S.M.).
A.C.M. and E.W. contributed equally to this work.
Disclosures: None declared.Hyaluronan (HA) is a linear glycosaminoglycan, which is a
ubiquitous component of extracellular matrix and has a
major role in regulating cellular processes, such as cellecell
adhesion,1 migration,2e4 differentiation,5,6 and pro-
liferation.7e9 HA is therefore implicated in influencing
numerous biological processes, and dysregulation of HA
synthesis, turnover, and binding interactions contributes to a
multitude of disease states, such as atherosclerosis, chronic
inflammation, cancer progression, and fibrosis.10e13
Hyaluronidase (HYAL)-2 has been identified as one of
the principal enzymes involved in HA catabolism in verte-
brates. HYAL2 is broadly expressed in tissues but has
catabolic function within only a narrow acidic pH rangeier Inc. on behalf of the American Society for
Y license (http://creativecommons.org/licenses(optimal pH, 4), and compared to other HYALs, has only
weak intrinsic HA-degrading activity.14 HYAL2 was orig-
inally identified as a lysosomal enzyme but was also sub-
sequently identified as anchored to the cell membrane via a
glycosylphosphatidylinositol link.15 Aberrant expression of
HYAL2 is implicated in diverse pathology, including car-
diac and skeletal abnormalities, hematopoietic and platelet
dysfunction, cancer, and fibrosis.16e21 However, manyInvestigative Pathology.
/by/4.0).
HYAL2 Governs RhoA Driven Cell Responsesreports indicate that a significant proportion of expressed
HYAL2 may be enzymatically inactive; thus the cellular
function of HYAL2 and the mechanisms through which
HYAL2 dysregulation influences pathology have been
previously unclear.14,15,22 A number of studies have iden-
tified that HYAL2 can also have important nonenzymatic
functions: Glycosylphosphatidylinositol-anchored HYAL2
has been identified as acting as a co-receptor for the trans-
membrane glycoprotein CD44, as a regulator of trans-
forming growth factor (TGF)-b1emediated intracellular
WW domainecontaining oxidoreductase 1 signaling, and as
a viral entry receptor.23e26 More recently, it was determined
that glycosylphosphatidylinositol-anchored HYAL2 can
translocate to the nucleus and regulate alternative splicing
events that influence differentiation to profibrotic cell
phenotypes.27
Myofibroblasts are the principal effector cells that drive
progressive fibrosis, a process that underlies many organ-
specific diseases and contributes to the burden of multi-
morbid conditions, including chronic kidney disease, lung
fibrosis, liver cirrhosis, and degenerative joint dis-
ease.28e33 Therefore, the study of factors that can either
promote or prevent cell differentiation to a myofibroblast
phenotype is important in identifying new therapeutic
approaches to the treatment of chronic disease. Myofi-
broblasts are derived from differentiation of resident fi-
broblasts, pericytes, or epithelial cells under the influence
of circulating profibrotic cytokines, such as TGF-
b1.13,34e36 HA and the most widely expressed isoform of
the HA receptor, CD44, are key mediators of myofibro-
blast differentiation.37e42 Specifically, the presence of
pericellular HA matrices tethered to cell-surface CD44 are
essential for TGF-b1edriven myofibroblast differentia-
tion. In contrast, cell-surface expression of an alternatively
spliced variant isoform of CD44 (denoted CD44v7/8)
promotes prevention and/or reversal of TGF-b1edriven
myofibroblast differentiation by causing internalization of
pericellular HA matrices.27,43 Nuclear HYAL2 was iden-
tified as a key modulator of CD44 mRNA alternative
splicing leading to attenuated standard CD44 expression,
while augmenting CD44v7/8 splice variant expression.
The purpose of this study was to determine the function
of HYAL2 in myofibroblasts relevant to its cell localization.
We report that cytoplasmic HYAL2 has distinct functions
compared to nuclear HYAL2. In contrast to our previous
studies demonstrating the antifibrotic actions of nuclear
HYAL2,27 we show that cytoplasmic HYAL2 in myofi-
broblasts can bind to the actin cytoskeleton and function as a
master regulator of TGF-b1edriven RhoA signaling.
Through this, HYAL2 promotes key profibrotic myofibro-
blast functions, including myofibroblast contractility,
collagen deposition, and CTGF (CCN2) and MMP2 mRNA
expression. These emerging studies from our group and
others begin to explain the broad biological effects of
HYAL2 and identify it as a key molecule for future study in
chronic disease.The American Journal of Pathology - ajp.amjpathol.orgMaterials and Methods
Materials
All reagents were purchased from Sigma-Aldrich (Poole,
UK) or Thermo Fisher Scientific (Paisley, UK) unless
otherwise stated. Reverse-transcription reagents, siRNA
transfection reagents, and real-time quantitative PCR (qPCR)
primers and reagents were purchased from Thermo Fisher
Scientific. Other reagents used were recombinant human
TGF-b1 (R&D Systems, Abingdon, UK) and the RhoA in-
hibitor Rhosin (G04; Merck Millipore, Watford, UK).
Animal Experiments Using Ischemia Reperfusion
InjuryeInduced Renal Fibrosis
Ten adult (8-weekeold to 12-weekeold) male Lewis rats
weighing 180 to 220 g were used (Harlan Laboratories, Ltd.,
Derby, UK). The rats acclimated to their surroundings for 7
days, with housing, handling, and experimental procedures in
accordance with the local institutional policies and procedures
licensed by the UK Home Office under the Animals (Scientific
Procedures) Act (1986). Rats (n Z 5 in each treatment group)
were provided with analgesics (200 mg of buprenorphine dis-
solved in 500 mL of drinking water) from 24 hours before
surgery until kidney retrieval. Animals were anesthetized with
isoflurane, a midline laparotomy incision made, and the renal
pedicles were identified and clamped for 45 minutes using a
vascular clip (ischemia reperfusion injury group). The kidney
was visually assessed for both ischemia upon clamping and
reperfusion upon release of the clamp. Rats in the sham group
underwent the same operation without renal pedicle clamping
(n Z 5). The rats were maintained for 28 days in accordance
with local institutional policies and procedures. At 28 days,
kidney tissue was retrieved with the animals under terminal
anesthesia and stored in formalin.Kidneyswere later embedded
in paraffin and sections of 4 mm in thickness were cut. Sections
were deparaffinized and rehydrated using xylene and reducing
concentrations of ethanol. Antigen retrieval was performed in
an autoclave using sodium citrate buffer with Tween. After
blocking of nonspecific sites, sections were incubated with 6
mg/mL anti-HYAL2 (goat anti-human polyclonal species
reactivity includes rat; Abcam, Cambridge, UK) and antiea-
smooth muscle actin (SMA)monoclonal antibody 1A4 (mouse
anti-human species reactivity includes rat; Thermo Fisher Sci-
entific). Fluorescence-labeled secondary antibodies used were
donkey anti-goat (H þ L) Alexa Fluor 555 (Thermo Fisher
Scientific) for HYAL2 and goat anti-mouse IgG (Hþ L) Alexa
Fluor 488 (Thermo Fisher Scientific) for a-SMA. DAPI was
used for nuclear staining and sectionswere analyzed using laser
scanning confocal microscopy.
Cell Culture
Human lung fibroblasts (AG02262) were purchased from
Coriell Cell Repositories (Coriell Institute for Medical1237
Table 1 Primer Sets Used in Quantitative RT-PCR Experiments
Target Sequences
HYAL2 F: 50-CGGACTCCCACACAGTTCCT-30
R: 50-CCAGGGCCAATGTAACGGT-30
EDA-FN F: 50-GCTCAGAATCCAAGCGGAGA-30
R: 50-CCAGTCCTTTAGGGCGATCA-30
TGFB1 F: 50-CCTTTCCTGCTTCTCATGGC-30
R: 50-ACTTCCAGCCGAGGTCCTTG-30
CCN2 F: 50-GGCCCAGACCCAACTATGAT-30
R: 50-AGGCGGCTCTGCTTCTCTA-30
FN1 F: 50-CCGAGGTTTTAACTGCGAGA-30
R: 50-TCACCCACTCGGTAAGTGTTC-30
MMP2 F: 50-CGTCGCCCATCATCAAGTTC-30
R: 50-CAGGTATTGCACTGCCAACTC-30
COL1A1 F: 50-TGTTCAGCTTTGTGGACCTCCG-30
R: 50-CGCAGGTGATTGGTGGGATGTCT-30
COL1A2 F: 50-GGCTCTGCGACACAAGGAGT-30
R: 50-TGTAAAGATTGGCATGTTGCTAGGC-30
GAPDH F: 50-CCTCTGACTTCAACAGCGACAC-30
R: 50-TGTCATACCAGGAAATGAGCTTGA-30
ACTA2 TaqMan assay gene ID Hs00426835_g1 (Thermo
Fisher Scientific, Paisley, UK)
18S rRNA Product code 4310893E (Thermo Fisher Scientific)
F, forward; R, reverse.
Midgley et alResearch, Camden, NJ). The cells were cultured in Dul-
becco’s modified Eagle’s low-glucose medium and Ham’s
F-12 containing 5 mmol/L glucose, 2 mmol/L L-glutamine,
100 U/mL penicillin, and 100 mg/mL streptomycin, and
supplemented with 10% fetal bovine serum (Biological In-
dustries Ltd., Cumbernauld, UK). The cells were maintained
at 37C in a humidified incubator in an atmosphere of 5%
CO2, and fresh growth medium was added to the cells every
3 days until the cells were ready for experimentation. The
cells were incubated in serum-free medium for 48 hours
before use in all experiments (growth arrest), and all ex-
periments were performed under serum-free conditions un-
less otherwise stated. All experiments were undertaken
using cells at passages 6 to 10.
RT-PCR and qPCR
qPCR was used to assess mRNA expression levels of
a-SMA (ACTA2), hyaluronidase 2 (HYAL2), extra domain-
Aefibronectin (EDA-FN), transforming growth factor beta 1
(TGFB1), [cellular communication network factor 2
(CCN2), also known as connective tissue growth factor
(CTGF)], fibronectin (FN1), collagen I [collagen type I
alpha 1 chain (COL1A1)] and collagen type I alpha 2 chain
(COL1A2), and matrix metallopeptidase 2 (MMP2). Primers
were commercially designed and purchased from Thermo
Fisher Scientific (Table 1). The cells were grown in 35-mm
dishes and washed with phosphate-buffered saline (PBS)
before lysis with TRI Reagent and RNA purification ac-
cording to the manufacturer’s protocol. Reverse-
transcription used high-capacity cDNA reverse-
transcription kits, according to the manufacturer’s pro-
tocols (Thermo Fisher Scientific). The kits use the random
primer method for initiating cDNA synthesis. As a negative
control, reverse-transcription was done with RNase-free,
sterile H2O replacing the RNA sample. qPCR was done
using the ViiA 7 Real-Time qPCR System (Thermo Fisher
Scientific) in a final volume of 20 mL per sample, as follows:
1 mL of reverse-transcription product, 0.6 mL of target gene
forward primer, 0.6 mL of target gene reverse primer, 10 mL
of Power SYBR Green PCR Master Mix, and 7.8 mL of
sterile RNase-free water. Amplification was done using a
cycle of 95C for 15 seconds and 60C for 1 minute for 40
cycles, followed by a melt-curve stage at 95C for 15 sec-
onds, 60C for 1 minute, and a final step of 95C for 15
seconds. qPCR was simultaneously performed for GAPDH
(primers and probe commercially designed and purchased
from Thermo Fisher Scientific) as a standard reference gene.
As a negative control, qPCR was performed with nuclease-
free, sterile H2O replacing the cDNA sample. The
comparative Ct method was used for relative quantification
of gene expression. The Ct (threshold cycle where ampli-
fication is in the linear range of the amplification curve) for
the standard reference gene (GAPDH ) was subtracted from
the target gene Ct to obtain the DCt. The mean DCt values
for replicate samples were then calculated. The expression1238of the target gene in experimental samples relative to
expression in control samples was then calculated using the
following equation: 2[DCt(1)DCt(2)], where DCt(1) is the
mean DCt calculated for the experimental samples, and
DCt(2) is the mean DCt calculated for the control samples.
Immunocytochemistry
Cells were grown to 70% confluence in eight-well Perma-
nox chamber slides. The culture medium was removed, and
the cells washed with sterile PBS before fixation in 4%
paraformaldehyde for 10 minutes at room temperature. After
fixation, cells were permeabilized with 0.1% (v/v) Triton X-
100 in PBS for 10 minutes at room temperature. Slides were
blocked with 1% bovine serum albumin (BSA) for 1 hour
before a further washing step with 0.1% (wt/v) BSA in PBS.
Subsequently, the slides were incubated with the primary
antibody diluted in 0.1% BSA and PBS for 2 hours at room
temperature. After a further washing step, slides were
incubated with Alexa Fluor 488econjugated and/or Alexa
Fluor 594econjugated secondary antibodies for 1 hour at
room temperature. Cell nuclei were stained with Hoechst
solution. Cells were then mounted and analyzed by confocal
and fluorescent microscopy. The following primary anti-
bodies were used: mouse anti-human a-SMA (Sigma-
Aldrich) and rabbit anti-human HYAL2 antibody (Atlas
Antibodies, Sigma-Aldrich). The following secondary anti-
bodies were used: goat anti-mouse Alexa Fluor 488, goat
anti-rabbit Alexa Fluor 594 (InvitroGen/Thermo Fisher
Scientific). For visualization of F-actin, fluorescein iso-
thiocyanateeconjugated phalloidin toxin was used in placeajp.amjpathol.org - The American Journal of Pathology
Figure 1 Hyaluronidase (HYAL)-2 demon-
strates increased interstitial expression in renal
fibrosis in areas of a-smooth muscle actin (SMA)e
positive myofibroblasts. Adult male Lewis rats
underwent a midline laparotomy and were divided
into two groups: sham operation (A) and bilateral
ischemia reperfusion injury (IRI) (cross-clamping
of both renal pedicles for 45 minutes) (B). At 28
days postoperatively, kidney tissue was retrieved
with the animals under terminal anesthesia and
stored in formalin. Kidneys were later embedded in
paraffin and sections of 4 mm in thickness were
cut. Sections were deparaffinized and rehydrated
using xylene and reducing concentrations of
ethanol. Antigen retrieval was performed in an
autoclave using sodium citrate buffer with Tween.
After blocking of nonspecific sites, sections were
incubated with anti-HYAL2 and a-SMA monoclonal
antibodies with appropriate fluorescence-labeled
secondary antibodies [HYAL2 Alexa Fluor 555
(red) and a-SMA Alexa Fluor 488 (green)] and
DAPI nuclear staining (blue). Sections were
analyzed using confocal microscopy. Areas depic-
ted as yellow demonstrate areas of Hyal2 and a-
Sma colocalization. Dashed circle indicates a
glomerulus; solid circles, tubules; arrowheads,
blood vessels; dashed arrows, areas of red blood
cell autofluorescence to be disregarded; solid ar-
rows, the renal interstitium between the tubules
where fibroblasts and myofibroblasts reside. n Z 5
per group. Scale bars Z 50 mm. Original magnifi-
cation, 400 (A and B, top rows); 630 (A and
B, bottom rows).
HYAL2 Governs RhoA Driven Cell Responsesof primary antibodies (Sigma-Aldrich). The total HYAL2
intensity of expression was quantified, and localization was
measured and quantified to regions of the cells using ImageJ
software version 1.37c (NIH, Bethesda, MD; http://imagej.
nih.gov/ij) and the Wright Cell Imaging Facility Intensity
Correlation Analysis plug-in.
siRNA Transfection
Fibroblasts were transiently transfected with specific siRNA
nucleotides (Thermo Fisher Scientific) targeting HYAL2.
Transfection was done using Lipofectamine 2000 trans-
fection reagent (InvitroGen/Thermo Fisher Scientific) in
accordance with the manufacturer’s protocol. Briefly, cellsThe American Journal of Pathology - ajp.amjpathol.orgwere grown to 50% to 60% confluence in antibiotic-free
medium in either 35-mm dishes or eight-well Permanox
chamber slides. Transfection reagent (2% v/v) was diluted
in Opti-MEM reduced growth medium (Gibco/Thermo
Fisher Scientific) and left to incubate for 5 minutes at room
temperature. HYAL2 siRNA (siHYAL2) oligonucleotides
were diluted in Opti-MEM reduced growth medium to
achieve a final concentration of 30 nmol/L. The transfection
reagent and siRNA mixtures were then combined and
incubated at room temperature for an additional 20 minutes.
The newly formed transfection complexes were subse-
quently added to the cells and incubated at 37C with 5%
CO2 for 24 hours, before replacement with fresh serum-free
medium before experimentation. As a control, cells were1239
Figure 2 Hyaluronidase (HYAL)-2 is upregulated and relocated from the cell membrane to the cell cytoskeleton by transforming growth factor beta 1 (TGFB1)
stimulation. Fibroblasts were seeded into 35-mmcell culture plates and grown to confluentmonolayers. After 48 hours of growth arrest, cells were incubatedwith serum-
freemediumalone (control) or serum-freemedium containing 10 ng/mL TGF-b1 for 72 hours.A: Cells wereharvested, and RNAwas isolated and purified. Quantitative RT-
PCR was used to determine mRNA expression of HYAL2. B: Total protein was isolated and immunoblotted for total HYAL2 protein production. Densitometric analysis is
shown alongside. Blots are representative of three separate experiments. C: Fibroblasts were seeded into eight-well glass chamber slides and grown to 60% to 70%
confluence prior to growth arrest. Cells were treated with serum-free medium alone or serum-free medium containing 10 ng/mL TGF-b1. Cells were washed with
phosphate-buffered saline before fixation, permeabilization, and staining to visualize HYAL2 and F-actin expression/localization. Images were captured using confocal
laser scanning microscopy and are representative of three individual experiments. Total HYAL2 expression is expressed as a percentage of the total HYAL2 expression by
cellular localization.Arrowheads indicate areas of colocalization (yellow). HYAL2 localization quantification: F-actinestained regions (green channels) were isolated by
threshold settings using ImageJ software version 1.37c to identify cytoskeleton regions of interest (ROIs). A second ROI tracing the cell boundary was selected by
identifying cell membrane localization. Intensity of HYAL2 staining (red channel) in each region was expressed as a percentage fraction of the total HYAL2 staining. The
remaining HYAL2 staining was identified as cytoplasmic localization. Five cells per microscopic field were assessed, and a total of three microscopic fields were analyzed
per treatment condition.D: Fibroblastswere treated as inB and totalHYAL2proteinwas co-immunoprecipitated and subjected to immunoblot forb-actin,g-actin, anda-
smoothmuscle actin (SMA). Blots are representative of three separate experiments. E: Cells were treated as in C but with additional treatment of cytochalasin B, followed
by immunostaining for HYAL2 and F-actin. Images are representative of three individual experiments. Data are expressed as means  SEM of three independent ex-
periments. **P< 0.01. Scale barsZ 10 mm (C and E). Original magnification:600 (C);400 (E). con., control; GADPH, glyceraldehyde phosphate dehydrogenase.
Midgley et al
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Figure 3 Hyaluronidase (HYAL)-2 from cell lysates (CL) of myofibroblasts has no enzymatic action in hyaluronan (HA)-degradation assays. Fibroblasts were
grown to 70% confluence and were transiently transfected with pCR3.1 containing HYAL1 or HYAL2 coding regions. Control transient transfections were
performed with the corresponding empty vector. Cells were growth-arrested before incubation in serum-free medium containing 10 ng/mL transforming growth
factor beta 1 (TGFB1; TGF-b1). A: Total cellular RNA was extracted, purified, and analyzed by RT-PCR, and the products were separated on 3% agarose gels.
Controls were negative (ve) RT and negative (ve) PCR, where no polymerase enzyme was added to the reaction mixture. B: HA substrate gel zymography of
HYAL activity. The medium was collected, and the cells were extracted in lysis buffer. The HYAL activity was isolated from the conditioned medium (CM) and CL
by DEAE-Sephacel ion exchange and lyophilized. Positive controls consisted of diluted human serum. Polyacrylamide gel electrophoresis was performed
without SDS in a 7.5% polyacrylamide gel (þHA) and visualized by Alcian Blue and Coomassie Brilliant Blue stain. C: HYAL activity (circles) of CM and CL was
further analyzed by incubating with highemolecular-weight [3H]-HA. HA size distribution was examined and compared with the original [3H]-HA preparation,
incubated in the absence of the conditioned medium or CL concentrate (squares). All images are representative of four individual experiments. GADPH,
glyceraldehyde phosphate dehydrogenase.
HYAL2 Governs RhoA Driven Cell Responsestransfected with negative-control siRNA (scramble; a
sequence that bears no homology to the human genome)
(Thermo Fisher Scientific).
Overexpression Vector Generation and Transfection
The HYAL1 or HYAL2 open reading frame was inserted into
the vector pCR3.1 using a standard ligation reaction with T4
DNA ligase (New England BioLabs, Hitchin, UK). Amplifi-
cation of the cloned vector was performed via bacterial trans-
formation into one-shot competent Escherichia coli (New
England BioLabs) and grown overnight on ampicillin con-
taining agar. Single colonies were extracted, cloned, andThe American Journal of Pathology - ajp.amjpathol.orgDNA-purified according to the Miniprep Kit protocol (Sigma-
Aldrich). Cloned pCR3.1-HYAL1 or pCR3.1-HYAL2 vector
uptake of the insert was confirmed with DNA sequencing.
Transfection was done using Lipofectamine LTX transfection
reagent (InvitroGen/Thermo Fisher Scientific) in accordance
with the manufacturer’s protocol. Briefly, cells were grown to
50% to 60% confluence in antibiotic-free medium in either
35-mm dishes or eight-well Permanox chamber slides.
Transfection reagent (2% v/v) was diluted in Opti-MEM
reduced growth medium (Gibco/Thermo Fisher Scientific).
pCR3.1 overexpression vectors were diluted in Opti-MEM
reduced growth medium containing PLUS Reagent (1% v/v),
to achieve a final transfection concentration of 1.5 mg/mL. The1241
Figure 4 Inhibition of hyaluronidase (HYAL)-2 expression delays but does not prevent myofibroblast phenotype acquisition or transforming growth
factor beta 1 (TGFB1; TGF-b1)eassociated gene expression. Fibroblasts were grown to 50% confluence prior to transfection with negative control
(scrambled) siRNA or with siRNA targeting HYAL2 expression (siHYAL2). Cells were growth-arrested for 48 hours before treatment with serum-free medium
alone or serum-free medium containing 10 ng/mL TGF-b1 for 0, 24, 48, or 72 hours. A: Western blot was used to assess HYAL2 protein knockdown. B:
Quantitative RT-PCR (RT-qPCR) was used to assess HYAL2 mRNA knockdown. C: Cells were then washed with phosphate-buffered saline, fixed, and
permeabilized before staining to visualize a-smooth muscle actin (SMA). Images are representative of three individual experiments. DeF: RT-qPCR was
also used to assess TGF-b1eregulated expression of ACTA2 (a-SMA) (D), extra domain-Aefibronectin (EDA-FN) (E), and TGFB1 (F) mRNA after incubation
with either HYAL2 or scrambled siRNA. Data are expressed as means  SEM of three independent experiments. *P < 0.05, **P < 0.01, and
***P < 0.001. Scale bars Z 10 mm.
Midgley et altransfection reagent and plasmidmixtures were then combined
and incubated at room temperature for an additional 20 mi-
nutes. The newly formed transfection complexes were subse-
quently added to the cells and incubated at 37Cwith 5% CO2
for 24 hours, before replacement with fresh serum-free me-
dium before experimentation. As a control, cells were trans-
fectedwith empty pCR3.1 plasmid (mock transfection plasmid
containing no open reading frame cDNA). Negative RT ex-
periments were performed alongside HYAL1/HYAL2 mRNA
PCR to ensure that the vectors were not conveying false-
positive overexpression. Expression was confirmed by visu-
alization on a 2% agarose gel.1242HA Substrate Gel Zymography
Confluent monolayers of fibroblasts were cultured in T25
culture flasks, growth-arrested, and incubated in serum-free
medium containing 10 ng/mL TGF-b1 for up to 72 hours.
The conditioned medium (CM) was removed, and the cells
were extracted in lysis buffer. The CM and the cell lysate
(CL) were passed over DEAE-Sephacel ion-exchange col-
umns in 50 mmol/L Tris-HCl, pH 7.8. The flow-through
containing the HYAL enzymes was collected, dialyzed
against H2O, and lyophilized. The samples were recon-
stituted in 100 mL of H2O and mixed with an equal volumeajp.amjpathol.org - The American Journal of Pathology
Table 2 Mass Spectrometry Mascot Scores in Descending Order of Significance
Best
protein
accession
Best protein
description
Mascot
score
Total
peptides, n
(MS and
MS/MS)
Total
peptides
with
MS/MS
data, n Peptide 1 Peptide 2 Peptide 3
MYH9 Myosin-9
(NMMHCIIA)
158 (e Z 1.1e011) 26 4 VVFQEFR (e Z 0.018) GDLPFVVPRR
(e Z 0.081)
VSHLLGINVTDFTR
(e Z 0.23)
MYH9 Myosin-9
(NMMHCIIA)
170 (e Z 6.6e013) 24 3 VSHLLGINVTDFTR
(e Z 0.0024)
VVFQEFR
(e Z 0.016)
RGDLPFVVPR
(e Z 0.024)
POTEE POTE ankyrin
domain family
member E
121 (e Z 5.3e008) 13 1 SYELPDGQVITIGNER
(e Z 1.50  107)
POTEF POTE ankyrin
domain family
member F
118 (e Z 1.1e007) 12 1 SYELPDGQVITIGNER
(e Z 1.50  107)
ACTRT1 Actin-related
protein T1
101 (e Z 5.3e006) 10 1 AGLSGEIGPR
(e Z 0.012)
ACTRT1 Actin-related
protein T1
91 (e Z 5.7e005) 9 1 AGLSGEIGPR
(e Z 0.015)
ACTB Actin, cytoplasmic
1 (b)
132 (e Z 4.2e009) 8 1 SYELPDGQVITIGNER
(e Z 1.50  107)
ACTG1 Actin, cytoplasmic
2 (g)
132 (e Z 4.2e009) 8 1 SYELPDGQVITIGNER
(e Z 1.50  107)
ACTB Actin, cytoplasmic
1 (b)
161 (e Z 5.3e012) 7 1 SYELPDGQVITIGNER
(e Z 1.70  1010)
LASP1 Nebulin-related-
LIM/SH3 domain
protein 1
83 (e Z 0.00031) 29
VCL Vinculin 61 (e Z 0.057) 17
HYAL2 Governs RhoA Driven Cell Responsesof zymography loading buffer. Samples were loaded onto
SDS-free 7.5% polyacrylamide gels containing HA at a final
concentration of 0.17 mg/mL. Positive controls consisted of
1 mL of human serum diluted in 10 mL of H2O, mixed with
an equal volume of zymography loading buffer. Electro-
phoresis was performed in running buffer at 75 V for 3
hours on ice to prevent denaturation of the HYAL enzymes.
The gel was incubated in 0.1 mol/L sodium formate buffer,
pH 3.7 at 37C for 72 hours. The gel was stained with 0.5%
(wt/v) Alcian Blue and then with 0.1% (w/v) Coomassie
Brilliant Blue in 50% (v/v) methanol and 20% (v/v) acetic
acid. The gel was destained in 5% (v/v) methanol and 10%
(v/v) acetic acid. The gel was visualized and imaged using a
light-box.
Purification of [3H]-HA
Hexokinase-2 cells were used to prepare large quantities of
[3H]-HA for analysis of HYAL enzyme activity. Cells were
incubated with D-[3H]-glucosamine for 72 hours in serum-
free medium. The CM was removed and the [3H]-HA
isolated and subjected to size-exclusion chromatography on
a Sephacryl S-500 column equilibrated with 4 mol/L gua-
nidine buffer. The fractions corresponding to [3H]-HA, withThe American Journal of Pathology - ajp.amjpathol.orga size of >1000 kDa, were pooled. Detergent was removed
from [3H]-HA by passing over DEAE-Sephacel ion-ex-
change columns and washing bound [3H]-HA extensively
with water. The [3H]-HA was eluted with detergent-free
4 mol/L guanidine buffer. For HYAL activity assays
(50  103 dpm) [3H]-HA was dialyzed against H2O and
lyophilized.
Hyaluronidase Activity Assay
Confluent monolayers of fibroblasts were cultured in T25
culture flasks, growth-arrested and incubated in serum-free
medium containing 10 ng/mL TGF-b1 for up to 72 hours.
The CM was removed, and the cells were extracted in lysis
buffer. The CM and the CL were passed over DEAE-
Sephacel ion-exchange columns in 50 mmol/L Tris-HCl,
pH 7.8. The flow-through containing the HYAL enzymes
was collected, dialyzed against H2O, and lyophilized. The
samples were reconstituted in 100 mL of H2O and incu-
bated with 200 mL of 0.1 mol/L sodium formate, pH 3.7
containing [3H]-HA (50  103 dpm) for 72 hours. Controls
consisted of 100 mL of H2O, 200 mL of 0.1 mol/L sodium
formate buffer, pH 3.7 containing [3H]-HA (50  103
dpm), incubated for 72 hours in the absence of CM or CL.1243
Table 3 GO and InterPro Results from Mass Spectrometry Hits
Demonstrating Identified Relevant Pathways
Pathway ID GO process description
GO.0070527 Platelet aggregation
GO.0001895 Retina homeostasis
GO.0030168 Platelet activation
GO.0048871 Multicellular organismal homeostasis
GO.0050878 Regulation of body fluid levels
GO.0007409 Axonogenesis
GO.0007596 Blood coagulation
GO.0048667 Cell morphogenesis and neuron differentiation
GO.0061564 Axon development
Pathway ID GO pathway/function description
GO.0005938 Cell cortex
GO.0030863 Cortical cytoskeleton
GO.0072562 Blood microparticle
GO.0005925 Focal adhesion
GO.0031988 Membrane-bounded vesicle
GO.0015629 Actin cytoskeleton
GO.0070062 Extracellular exosome
GO.0005576 Extracellular region
GO.0071944 Cell periphery
GO.0005856 Cytoskeleton
Pathway ID InterPro function
IPR004001 Actin, conserved site
IPR020902 Actin/actin-like conserved site
IPR004000 Actin family
Pathway ID KEGG pathway
4810 Regulation of actin cytoskeleton
4520 Adherens junction
4670 Leukocyte transendothelial migration
4530 Tight junction
4510 Focal adhesion
KEGG, Kyoto Encyclopedia of Genes and Genomes.
Midgley et alThe samples were mixed with an equal volume of 4 mol/L
guanidine buffer and analyzed by size-exclusion chroma-
tography on a Sephacryl S-500 column equilibrated with 4
mol/L guanidine buffer or a Sepharose CL-4B column
(Amersham Pharmacia Biotech, Buckinghamshire, UK)
equilibrated with 4 mol/L guanidine buffer. HYAL activity
was assessed by comparing the [3H]-HA elution profiles,
incubated in the presence and absence of CM or CL.
HYAL activity was not detectable at neutral pH (data not
shown).Co-Immunoprecipitation
Cells were harvested into 1 mL of ice-cold PBS and
pelleted at 1000 g for 5 minutes before resuspension in
radioimmunoprecipitation assay lysis buffer. Supernatant
was transferred to new Eppendorfs and a known volume
of 25 mg of protein in radioimmunoprecipitation assay
buffer was immunoprecipitated using anti-HYAL21244antibody-linked anti-rabbit Dynabeads (InvitroGen/
Thermo Fisher Scientific). Beads were preincubated with
0/1% w/v BSA. Immunoprecipitation was completed
with an overnight rotating incubation at 4C. After three
washes with Nonidet P-40 buffer, the beads were
resuspended in PBS and transferred to clean micro-
centrifuge tubes. The bead-antibody-protein complex
was boiled with reducing buffer for 5 minutes before the
supernatant was transferred into gel lanes for SDS-
PAGE. Alternatively, eluted protein was assessed by
mass spectrometry (MS).
Mass Spectrometry
Co-immunoprecipitation elutes were loading into and run
on a 1.5-mm 7.5% polyacrylamide gel. Gel plugs were
manually excised and peptides recovered after trypsin
(6.25 ng/mL in 25 mmol/L NH4HCO3, 37C, 3 hours;
sequencing gradeemodified trypsin from Promega UK
Ltd., Southampton, UK) digestion using a modified
version of the method of Shevchenko et al.44 The dried
peptides were resuspended in 50% (v/v) acetonitrile in
0.1% (v/v) trifluoroacetic acid (5 mL) for MS analysis and
a 10% aliquot was spotted onto a 384-well MS plate. The
samples were allowed to dry and were then overlaid with
a-cyano-4-hydroxycinnamic acid [Sigma-Aldrich; 0.5 mL
of 5 mg/mL in 50% (v/v) acetonitrile and 0.1% (v/v) tri-
fluoroacetic acid]. MS was performed using a 4800
MALDI TOF/TOF mass spectrometer (Applied Bio-
systems, Thermo Fisher Scientific, Warringon, UK) with a
200-Hz solid-state laser operating at 355 nm (S3, S4).
MALDI mass spectra and subsequent MS/MS spectra of
the eight most abundant MALDI peaks were obtained after
routine calibration. Peaks were stringently selected and
were analyzed with the strongest peak first. For positive-
ion reflector mode spectra 800 laser shots were averaged
(mass range, 700 to 4000 Da; focus mass, 2000). In MS/
MS positive ion mode 4000 spectra were averaged with 1
kV collision energy (collision gas was air at a pressure of
1.6  106 Torr) and default calibration. Combined pep-
tide mass fingerprinting and MS/MS queries were per-
formed using the Mascot database search engine version
2.1 (Matrix Science Ltd., London, UK) embedded into
Global Proteome Server Explorer software version 3.6
(Applied Biosystems, Thermo Fisher Scientific) on the
Swiss-Prot database (https://www.uniprot.org, last
accessed January 9, 2013) or the TrEMBL database
(www.bioinfo.pte.hu/more/trembl.htm, download date
June 28, 2011).45 Searches were restricted to human
taxonomy with trypsin specificity (one missed cleavage
allowed), the tolerances were set for peptide
identification searches at 50 ppm for MS and 0.3 Da for
MS/MS. Cysteine modification by iodoacetamide was
employed as a fixed modification with methionine
oxidation as a variable modification. Search results were
evaluated by manual inspection, and conclusiveajp.amjpathol.org - The American Journal of Pathology
Figure 5 Proteins co-associated with hyaluronidase (HYAL)-2 have roles
in actin organization and contraction function. A: Functional
proteineprotein association networks of proteins identified from HYAL2 co-
immunoprecipitation and mass spectrometry. Protein web was created using
the STRING online database version 10.5.B: Kyoto Encyclopedia of Genes and
Genomes (KEGG) functional pathway of actin cytoskeleton organization.
Depth of green indicates strength of HYAL2eprotein association, as deter-
mined by tandem mass spectrometry peptide identification (where darker
green indicates stronger evidence of association). Previously demonstrated
HYAL2 associations are highlighted by stars. Pathway map was generated
using KEGG Mapper version 2.8 prior to adaption. ACTB, b-actin; ACTG, g-
actin; ACTN, a-actinin; ACTRT1, actin-related protein T1; ACTT, ACT-toxin
biosynthesis protein; ETV5, ETS variant transcription factor 5 [also known
as Ets-related protein (ERM)]; SLC2A4 regulator, guanineenucleotide ex-
change factor (also known as GEF); LASP, LIM and SH3 domain protein; mDia,
mammalian diaphanous-related formin; MLC1, modulator of VRAC current 1
[also known as membrane protein (MLC)]; MYLK, myosin light chain kinase
(also known as MLCK); MLCP, myosin light-chain phosphatase; MYH9, myosin
heavy chain 9 (also known asMNNCHIIA); NHE, Naþ/Hþ exchanger; PAK, p21-
activated kinase; PFN, profilin; PIP, phosphatidylinositol phosphate; POTEE,
prostate, ovary, testis-expressed (POTE) ankyrin domain family member E;
POTEF, POTE ankyrin domain family member F; ROCK, Rho-associated protein
kinase; TGF, transforming growth factor; VCL, vinculin. Panel B adapted with
permission from Kanehisa Laboratories.
HYAL2 Governs RhoA Driven Cell Responsesidentification confirmed whether there were high-quality
MS/MS (good y ion) data for two or more peptides (E
value P < 0.05 for each peptide; overall P < 0.0025) or
one peptide (only if the E value was P < 0.0001).The American Journal of Pathology - ajp.amjpathol.orgWestern Blot Analysis
Total protein was extracted in radioimmunoprecipitation
assay lysis buffer containing 1% protease inhibitor cocktail,
1% phenylmethylsulfonyl fluoride, and 1% sodium ortho-
vanadate (Santa Cruz Biotechnology, Santa Cruz, CA).
Protein was quantified before SDS-PAGE and transfer to
nitrocellulose. Membranes were blocked with 5% BSA/0.5%
Tween-20/PBS for 1 hour, room temperature, followed by
incubation with primary antibodies diluted in 1% BSA/0.1%
Tween-20/PBS, overnight at 4C. After wash steps, mem-
branes were incubated in secondary anti-rabbit/mouse IgG
horseradish peroxidase conjugate (Cell Signaling Technol-
ogy, Beverly, MA; 1:5000 dilution, 1% BSA/0.1% Tween-
20/PBS). Detection was performed using ECL reagent (GE
Healthcare, Buckinghamshire, UK) and image exposure on a
C-DiGit Western Blot Scanner (LI-COR, Bad Homburg vor
der Höhe, Germany). Primary antibodies used were rabbit
polyclonal to g-actin (Abcam), rabbit polyclonal to
phosphoemyosin light-chain kinase (MLCK) S1760
(Abcam), mouse monoclonal to b-actin (Cell Signaling
Technologies), mouse monoclonal antiea-SMA antibody
1A4 (Thermo Fisher Scientific), and rabbit polyclonal anti-
HYAL2 antibody (Sigma-Aldrich). Secondary antibodies
used were goat polyclonal antibody to mouse IgG horse-
radish peroxidase (Abcam) and goat polyclonal antibody to
rabbit IgG horseradish peroxidase (Abcam).
In Silico Analysis
MS data were input into STRING (STRING database version
10.5; String Consortium 2017, http://string-db.org, last
accessed July 1, 2017) and Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway (KEGG Pathway database,
http://www.genome.jp/kegg, last accessed February 20, 2020;
Kanehisa Laboratories, Kyoto, Japan) analysis tools.
STRING proteineprotein networks indicate known
proteineprotein associations and strength of association,
cross-referencing GO, InterPro and KEGG molecular
pathways indicate strength of specific pathway
involvement.46 KEGG pathway analysis was used to
determine the functional pathway in which the proteins
identified by MS were likely to be involved.
Collagen Gel Contraction Assays
Type I collagen was extracted from rat-tail tendon as previ-
ously described.47 Approximately 2.5  105 fibroblasts/mL
were mixed into collagen latticeeforming solutions (2.5 mL
20% v/v fetal calf serumeDulbecco’s modified Eagle’s low-
glucose medium, 500 mL of 0.1 mol/L NaOH, and 2 mg/mL
type I collagen; total volume of 5 mL). Fibroblast-populated
collagen lattices (FPCLs) were maintained at 37C, in a 5%
CO2 atmosphere for 1 hour, for collagen polymerization to
occur. FPCLs were gently detached from the plate edges and
resuspended in serum-free medium containing appropriate1245
Figure 6 Hyaluronidase (HYAL)-2 associates with and orchestrates ras homolog family member A (RhoA) activation and downstream myosin light-chain
kinase (MYLK; MLCK) activation. A: Fibroblasts were grown to 50% confluence prior to transfection with negative control (scramble) siRNA () or with siRNA
targeting HYAL2 expression (siHYAL2) (þ). After successful transfection and growth arrest, cells were incubated with 10 ng/mL transforming growth factor
(TGF)-b1 for the annotated times. At each time point, cells were harvested and protein from total cell lysate was isolated. Phosphorylation of RhoA and MLCK
were determined by Western blot. Total RhoA and MLCK were used as gel loading controls. B: The RhoA inhibitor Rhosin was used as an inhibitor of RhoA
activation. Fibroblasts were pretreated with 10 mmol/L Rhosin for 2 hours, prior to and during incubation with 10 ng/mL TGF-b1. Phosphorylation of RhoA and
MLCK were determined by Western blot. C: Fibroblasts were grown to confluence in culture and after 48 hours of growth arrest were incubated with either
serum-free medium containing 10 ng/mL TGF-b1 or serum-free medium alone (control). Anti-HYAL2 co-immunoprecipitation followed by Western blot for
MLCK, RhoA, and calcium/calmodulin-dependent protein kinase type II (CaMKII) was then performed. Western blots for HYAL2 were used as loading controls.
Positive (þve) controls were total cell lysate and negative (ve) controls were co-immunoprecipitation (IP) performed using rabbit Immunoglobulin G (IgG) in
place of anti-HYAL2 antibody. All blots are representative of three independent experiments. Densitometries are expressed as the means  SEM of three
independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001., con. control; min., minutes; p, phosphorylated.
Midgley et altreatments. FPCLs were measured at 0, 3, 6, 12, and 24 hours
after initial lattice fabrication. The mean FPCL contraction
valueswere obtained fromanalysis by ImageJ software version
1.37c (and are expressed as the percent reduction in gel
diameter compared to the gel diameter at 0 days).1246Scratch-Wound Migration Assays
Scratching quiescent fibroblasts cell monolayers with
sterile 200-mL pipette tips generated linear denuded areas.
The cells were gently washed with PBS to removeajp.amjpathol.org - The American Journal of Pathology
Figure 7 Ras homolog family member A (RhoA) regulates cellular communication network factor 2 [CCN2, also known as connective tissue growth factor
(CTGF)], fibronectin, matrix metallopeptidase 2 [MMP2, also known as matrix metalloproteinase (MMP)-2], and collagen I gene expression. Fibroblasts were
grown to confluent monolayers on 35-mm tissue culture plates. They were then growth-arrested and pretreated with either dimethyl sulfoxide (DMSO) alone
(as a control) or with 10 mmol/L Rhosin for 2 hours, prior to incubation with 10 ng/mL transforming growth factor beta 1 (TGFB1, also known as TGF-b1) for 0,
24, 48, or 72 hours. Quantitative RT-PCR was used to assess the effects of RhoA inhibition on mRNA expression of CTGF (A), fibronectin 1 (FN1) (B), MMP2 (C),
collagen type I alpha 1 chain (COL1A1) (D), and collagen type I alpha 2 chain (COL1A2) (E). Data are expressed as means  SEM of three independent
experiments. *P < 0.05, **P < 0.01, and ***P < 0.001.
HYAL2 Governs RhoA Driven Cell Responsesdetached cells and then replenished with fresh serum-free
medium containing appropriate treatments. The wound
size was photographed at 0, 3, 6, 12, and 24 hours or until
closure, using an Axiovert 100 mol/L inverted microscope
(Carl Zeiss, Oberkochen, Germany) fitted with a digital
camera (Orca-1394; Hamamatsu Photonics K.K., Hama-
matsu, Japan). Measurements were obtained using ImageJ
software version 1.37c. Data are expressed as the percent
reduction in wound area, compared to wound area at
0 hours.
Statistical Analysis
The two-tailed, unpaired t-test was used to assess statistical
differences between the two experimental groups. For ex-
periments with multiple experimental groups, one-way
analysis of variance was used to identify statistical differ-
ences across groups, followed by post-test Bartlett and
multiple comparisons. For experiments with multiple
experimental conditions, two-way analysis of variance was
used, followed by post-test Tukey multiple comparisons.
Graphical data are expressed as means  SEM. All data
were analyzed using GraphPad Prism software version 6
(GraphPad Software, San Diego, CA). P < 0.05 was
considered statistically significant.The American Journal of Pathology - ajp.amjpathol.orgResults
Increased HYAL2 Expression and Colocalization with
a-SMAePositive Myofibroblasts in the Renal
Interstitium after Experimental Renal Fibrosis in Vivo
To investigate the in vivo relevance of HYAL2 in progres-
sive fibrosis, we characterized HYAL2 expression, locali-
zation, and preponderance in relation to the expression of
the myofibroblast marker a-Sma in an experimental model
of renal fibrosis (Figure 1). Our established model of
bilateral renal ischemia was used to promote renal fibrosis in
rats as described in the methods, and comparisons were
made to sham controls. The results demonstrated that in
normal/sham kidneys (Figure 1A), HYAL2 staining was
present only in arterial blood vessels, where it colocalized
with a-Sma staining from vascular smooth muscle cells.
There was little/no HYAL2 staining in the glomeruli or in
the tubules. There was some nonspecific HYAL2 staining of
red blood corpuscles in the glomeruli and interstitium
consistent red cell autofluorescence, which is a common
phenomenon in the kidney. The renal interstitium is the
space between the renal tubules and glomeruli where the
fibroblasts/stromal cells reside. Resident fibroblasts were
seen in the renal interstitium; however, these demonstrated1247
Figure 8 Ras homolog family member A (RhoA)-dependent gene expression is attenuated by hyaluronidase [HYAL2, also known as (HYAL)-2]
knockdown. Fibroblasts were grown to 50% confluence prior to transfection with negative control (scramble) siRNA or with siRNA targeting HYAL2
expression (siHYAL2). Cells were subsequently growth-arrested before treatment with serum-free medium containing 10 ng/mL transforming growth
factor beta 1 [TGFB1, also known as (TGF)-b1], for 0, 24, 48, or 72 hours. Quantitative RT-PCR was used to assess the effects of HYAL2 knockdown on
mRNA expression of cellular communication network factor 2 (CTGF) (A), fibronectin 1 (FN1) (B), matrix metallopeptidase 2 (C), collagen type I alpha 1
chain (COL1A1) (D), and collagen type I alpha 2 chain (COL1A2) (E). Data are expressed as means  SEM of three independent experiments. *P < 0.05,
**P < 0.01.
Midgley et alno a-Sma expression, indicating that these cells had not
differentiated to a profibrotic myofibroblast phenotype. The
resident fibroblasts demonstrated little/no HYAL2
expression.
Kidneys harvested from rats that had undergone ischemia
reperfusion injuryeinduced renal fibrosis (Figure 1B) also
demonstrated positive HYAL2 staining in arterial blood
vessels, and this similarly colocalized with a-Sma expres-
sion from vascular smooth muscle cells. However, in these
kidney sections there was also clear evidence of increased
expression of a-Smaepositive myofibroblasts in the renal
interstitium. The areas of interstitial a-Smaepositive stain-
ing also demonstrated increased HYAL2 expression, which
colocalized with a-Smaepositive areas. The top panel of
images in Figure 1B (from rodents that underwent ischemia
reperfusion injury) depicts an area of fibrosis with relatively
preserved renal architecture with undamaged renal tubules.
In these images there is a-Smaepositive myofibroblast
staining with associated HYAL2 staining and colocalization
of these two proteins in the renal interstitium. The lower
panel of images in Figure 1B depicts an area of gross
fibrosis with disordered renal tubular architecture and
increased a-Smaepositive myofibroblast staining in the
renal interstitium. These areas of enhanced fibrosis and
damage also demonstrated increased levels of HYAL21248staining and colocalization with a-Smaepositive myofi-
broblasts. These data indicate that during progressive
fibrosis, there is increased differentiation to and expansion
of the a-SMAepositive myofibroblast cell population in the
renal stroma, and that HYAL2 expression is increased in
this cell population and colocalizes with a-SMAepositive
cytoskeleton.
Increased HYAL2 Expression in Myofibroblasts
Associated with the Cell Cytoskeleton
Exposure of human fibroblasts to 10 ng/mL TGF-b1 for 72
hours was previously demonstrated to induce terminal
myofibroblast differentiation.14,43 Fibroblasts were stimu-
lated with this established dose and duration of TGF-b1 to
induce stable myofibroblast differentiation and expression
of HYAL2 mRNA assessed by qPCR. Myofibroblasts had
significantly increased expression of HYAL2 mRNA
compared to undifferentiated fibroblasts (Figure 2A), and
this finding was reciprocated on detection of total HYAL2
protein present in CLs (Figure 2B). The cellular localiza-
tion of HYAL2 was next determined. Immunofluorescence
staining for HYAL2 and filamentous actin demonstrated
that in undifferentiated fibroblasts, HYAL2 was predom-
inantly localized at the cell surface, while in differentiatedajp.amjpathol.org - The American Journal of Pathology
Figure 9 Ras homolog family member A (RhoA) inhibition does not
attenuate hyaluronidase 2 (HYAL2) mRNA or hyaluronidase (HYAL)-2 pro-
tein expression. Fibroblasts were grown to confluent monolayers on 35-mm
tissue culture plates. They were then growth-arrested and pretreated with
either dimethyl sulfoxide (DMSO) alone (as a control) or with 10 mmol/L
Rhosin for 2 hours, prior to and during incubation with 10 ng/mL trans-
forming growth factor beta 1 [TGFB1, also known as (TGF)-b1] for 72 hours.
A: Quantitative RT-PCR was used to assess the effect of RhoA inhibition on
HYAL2 mRNA expression. B: Western blot was used to assess the effect of
RhoA inhibition on HYAL2 protein expression. GAPDH, glyceraldehyde
phosphate dehydrogenase.
HYAL2 Governs RhoA Driven Cell Responsesmyofibroblasts, HYAL2 was localized along and around
the actin cytoskeleton (Figure 2C). To confirm the nature
of HYAL2 association with the actin cytoskeleton in
myofibroblasts in culture, the cells were assessed for co-
immunoprecipitation of cytoskeletal components
including b-actin, g-actin, and a-SMA in undifferentiated
and TGF-b1edifferentiated myofibroblasts. The immu-
noblots indicated that after TGF-b1edriven myofibroblast
differentiation there was increased association between
HYAL2 and a-SMA (Figure 2D). To further confirm this
finding, cells were treated with cytochalasin B to prevent
actin filament polymerization prior to immunofluorescence
for HYAL2. Disruption of the actin cytoskeleton by pre-
venting filamentous actin polymerization also led to the
disruption of cytoplasmic HYAL2, confirming that
HYAL2 associates with the a-SMA cytoskeleton in
myofibroblasts (Figure 2E).The American Journal of Pathology - ajp.amjpathol.orgHA Catabolic Activity of Cell-Associated HYAL2 in
Myofibroblasts
To determine the catabolic effects of HYAL2 in myofi-
broblasts, these cells were transiently transfected with
plasmid vector (pCR3.1) containing the HYAL2 coding
region. To compare catabolic activity of HYAL2 with the
catabolic activity of the other widely expressed HYAL
enzyme in vertebrates, HYAL1, fibroblasts were also
transfected with plasmid vector (pCR3.1) containing the
HYAL1 coding region. Semi-quantitative RT-PCR was
used to examine the mRNA expression of HYAL1 and
HYAL2 in fibroblasts transiently transfected with pCR3.1-
HYAL1 and pCR3.1-HYAL2. Control transfection was
performed with the empty vector pCR3.1. Endogenous
HYAL1 and HYAL2 mRNA expression was detected in
control transfections. Transfection with pCR3.1-HYAL1
resulted in increased HYAL1 mRNA expression compared
to transfection with the empty vector. Transfection with
pCR3.1-HYAL2 resulted in increased HYAL2 mRNA
expression compared to the empty vector (Figure 3A). HA
substrate gel zymography of HYAL activity of fibroblasts
transiently transfected with pCR3.1-HYAL1 and
pCR3.1-HYAL2 was undertaken. Control transfections
were undertaken with the empty vector pCR3.1. The
HYAL activity was isolated from the CM and CL by
DEAE-Sephacel ion-exchange and lyophilized. The
HYAL activity was analyzed by HA-substrate gel
zymography at pH 3.7. HYAL activity was represented as
a clear band in the polyacrylamide gel, due to the
exclusion of the Alcian Blue and Coomassie Brilliant
Blue stains. Endogenous HYAL activity was not detected
in the CM or CL of control transfections. Transfection
with pCR3.1-HYAL1 resulted in significant HYAL activ-
ity detected in both the CM and CL. However, trans-
fection with pCR3.1-HYAL2 did not result in any
detectable HYAL activity in either CM or CL (Figure 3B).
To confirm these results, cells transiently transfected with
either pCR3.1 alone, pCR3.1-HYAL1, or pCR3.1-HYAL2
were isolated from the CM and CL by DEAE-Sephacel
ion-exchange chromatography and lyophilized. The CM
and CL were incubated with highemolecular-weight
[3H]-HA at pH 3.7 for 72 hours. The samples were then
subjected to size-exclusion chromatography and HYAL
activity assessed by comparing the elution profiles of the
[3H]-HA incubated in the presence or absence of CM or
CL. Endogenous HYAL activity was detected in the CM
of the control transfections with pCR3.1 alone, partially
degrading the HA to loweremolecular-weight forms.
Transfection with pCR3.1-HYAL1 increased the HYAL
activity detected in the CM compared to the control
transfection. The CL contained relatively less HYAL ac-
tivity, only partially degrading the HA. Transfection with
pCR3.1-HYAL2 increased the HYAL activity in the CM
compared to control transfections with pCR3.1 alone.
HYAL activity was not detected in the CL of cells1249
Figure 10 Ras homolog family member A (RhoA) regulates transforming growth factor beta 1 (TGFB1, also known as TGF-b1)edependent contractility and
migration in myofibroblasts. Fibroblasts were grown to confluent monolayers, growth-arrested for 48 hours, and then treated with 10 mmol/L Rhosin for 2
hours prior to and during TGF-b1 incubation. A: Cells were seeded into collagen gels and left to polymerize before incubation in serum-free medium alone or
serum-free medium containing 10 ng/mL TGF-b1. Collagen gels were imaged over the annotated time points and measured for analysis of rate of contraction.
Dotted lines indicate the measured gel areas at this time point. B: Cells were growth-arrested and scratched using a 20 mL pipette tip. After a phosphate-
buffered saline wash, the medium was replaced with fresh serum-free medium or serum-free medium containing 10 ng/mL TGF-b1. Scratch assays were imaged
at the indicated time points, and the area of closure was measured to assess rate of migration. Dotted lines represent the original scratch edges. Data are
expressed as means  SEM of three individual experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 control þ TGF-b1 versus treated þ TGF-b1; yP < 0.05,
yyP < 0.01 control versus treated samples; zzzP < 0.001 control versus control þ TGF-b1 samples. DMSO, dimethyl sulfoxide.
Midgley et altransfected with pCR3.1-HYAL2 at all, indicating that
cell-associated HYAL2 is inactive in myofibroblasts
(Figure 3C).
HYAL2 Involvement in Mediating TGF-b1eDriven
Myofibroblast Differentiation
Myofibroblasts demonstrate cytoskeletal reorganization
compared to undifferentiated fibroblasts. Fibroblasts
generally demonstrate a narrow, spindle-shaped appear-
ance with actin fibers forming a complex cortical mesh-
work at the periphery of cells. In myofibroblasts, the actin
fibers coalesce to form thick parallel stress fibers that run
from end to end of the cells, and the contractile protein
a-SMA is incorporated into these stress fibers.34,35 In view
of the results from Figures 1 and 2 indicating that HYAL2
demonstrated association with and relocalization to1250associate with the actin cytoskeleton as fibroblasts un-
derwent differentiation to myofibroblasts, a link between
HYAL2 and myofibroblast differentiation was investi-
gated. siRNAs targeting HYAL2 (siHYAL2) were used to
determine the role of this protein in TGF-b1edriven
myofibroblast differentiation. Successful knockdown of
HYAL2 mRNA and HYAL2 protein expression, after
siRNA treatment compared with scrambled controls, was
initially confirmed (Figure 4, A and B). The influence of
HYAL2 knockdown on a-SMA protein expression was
subsequently assessed. There were no significant effects of
siHYAL2 transfection versus control (scrambled siRNA
transfection) on a-SMA incorporation into myofibroblast
stress fibers as visualized through immunofluorescence
(Figure 4C). The effects of HYAL2 knockdown on ACTA2
(a-SMA) mRNA expression assessed by qPCR similarly
demonstrated no effects on terminal myofibroblastajp.amjpathol.org - The American Journal of Pathology
Figure 11 Hyaluronidase (HYAL2, also known as HYAL-2) mediates Ras homolog family member A (RhoA)-dependent contractility and migration
in myofibroblasts. Fibroblasts were grown to 50% confluence prior to transfection with negative control (scramble) siRNA or with siRNA targeting
HYAL2 expression (siHYAL2). A: Cells were seeded into collagen gels and left to polymerize before incubation in serum-free medium alone or serum-
free medium containing 10 ng/mL transforming growth factor (TGF)-b1. Collagen gels were imaged over the annotated time points and measured
for analysis of rate of contraction. Lines indicate the measured gel areas at this time point. B: Cells were growth-arrested and scratched using a
20-mL pipette tip. After a phosphate-buffered saline wash, the medium was replaced with fresh serum-free medium or serum-free medium con-
taining 10 ng/mL TGF-b1. Scratch assays were imaged at the indicated time points, and the area of closure was measured to assess the rate of
migration. Lines represent the original scratch edges. Data are expressed as the means  SEM of three individual experiments. *P < 0.05,
**P < 0.01, and ***P < 0.001 control þ TGF-b1 versus treated þ TGF-b1; yyP < 0.01 control versus treated samples; zP < 0.05, zzP < 0.01,
zzzP < 0.001 control versus control þ TGF-b1 samples.
HYAL2 Governs RhoA Driven Cell Responsesdifferentiation at 72 hours (Figure 4D). Although there
was a delay in increased ACTA2 mRNA expression at 24
and 48 hours, at 72 hours after TGF-b1 stimulation
ACTA2 mRNA expression in fully differentiated myofi-
broblasts was comparable in siHYAL2-treated versus
scrambled-siRNAetreated cells. EDA splice variant FN is
another characteristic myofibroblast marker necessary for
acquisition of this profibrotic phenotype.48,49 The influ-
ence of siHYAL2 transfection on EDA-FN mRNA
expression also demonstrated that while HYAL2 knock-
down delayed increased EDA-FN mRNA expression, it did
not influence EDA-FN mRNA expression in differentiated
myofibroblasts (Figure 4E). HYAL2 knockdown also did
not influence autoinduction of TGFB1 mRNA expression
in myofibroblasts, indicating that overall HYAL2 did not
influence TGF-b1edependent terminal myofibroblast dif-
ferentiation (Figure 4F).The American Journal of Pathology - ajp.amjpathol.orgHYAL2 Binding to RhoA and Myosin Light-Chain Kinase
and Modulation of Phosphorylation of These Proteins
MS was used to identify important HYAL2 cellular in-
teractions in myofibroblasts. The Mascot score was used
to justify the accuracy of protein identification, and
Table 2 lists the proteins identified in descending order of
significance. HYAL2 was identified as associating with
actin-related cytoskeletal remodeling proteins (actin-
related protein T1, b-actin, g1-actin), contractile proteins
(myosin heavy chain 9), prostate, ovary, testis-expressed
ankyrin domain family members E/F; vinculin; and LIM
and SH3 domain protein 1. Table 3 shows the GO and
InterPro results from uploading the MS hits and demon-
strates the lists of relevant pathways with these hits. To
summarize the proteomics results into a general functional
model, the known and predicted proteineprotein1251
Midgley et alinteractions were built using the STRING database
network and demonstrated that all of the proteins are
closely related, providing additional evidence that
HYAL2 is involved in pathways consisting of these pro-
teins (Figure 5A). Of the suggested pathways, actin
cytoskeleton regulation was selected because of the ob-
servations demonstrating that HYAL2 aligns with the cell
cytoskeleton (Figure 5B). Figure 5B also demonstrates the
strength of HYAL2eprotein associations within that
pathway. This analysis indicates a putative link between
HYAL2, RhoA, and MLCK.
To conclusively determine the association between the
HYAL2 and RhoA pathways, fibroblasts stimulated with
TGF-b1 were transfected with either siHYAL2 or scrambled
siRNA. Subsequent Western blot analysis to assess RhoA
and MLCK phosphorylation was undertaken and compared
to total RhoA and MLCK, respectively, as a control. The
results demonstrated that HYAL2 knockdown significantly
attenuated RhoA phosphorylation at all time points after
TGF-b1 stimulation. HYAL2 knockdown also attenuated
MLCK phosphorylation at 15, 30, 60, and 120 minutes after
TGF-b1 stimulation. These results were confirmed by
densitometric analysis of Western blot bands indicating
statistically significant attenuation of RhoA and MLCK
activation after HYAL2 knockdown (Figure 6A). To deter-
mine the signaling of the link between RhoA and MLCK, a
chemical inhibitor of RhoA (Rhosin) was used in subse-
quent experiments. The data indicated that Rhosin effec-
tively attenuated RhoA phosphorylation. Furthermore,
RhoA inhibition with Rhosin also abrogated MLCK phos-
phorylation at 15, 30, 60, and 120 minutes after TGF-b1
stimulation, and this was confirmed on densitometric anal-
ysis (Figure 6B). Co-immunoprecipitation was used to
examine any direct interaction between these proteins, and
the results indicated that HYAL2 interacts directly with
RhoA in both fibroblasts and myofibroblasts. HYAL2 also
interacts with MLCK, and this interaction is increased after
stimulation with TGF-b1. Previous work has demonstrated
an important role for calcium/calmodulin-dependent protein
kinase type II signaling in mediating TGF-b1edriven
fibroblast to myofibroblast differentiation.42 This study
therefore also tested for direct interactions between HYAL2
and calcium/calmodulin-dependent protein kinase type II
and identified no association between these two proteins
(Figure 6C).
Attenuated Expression of RhoA-Dependent Genes after
HYAL2 Knockdown
RhoA is a small GTPase protein in the Rho family, which
has been implicated in regulating several fibrogenic genes
including collagens, FNs, matrix metalloproteinases
(MMPs), and connective tissue growth factor [CTGF; also
known as cellular communication network factor
(CCN2)].50e54 To confirm the involvement of RhoA in the
regulation of these genes in our experimental cell systems,1252fibroblasts were incubated with 10 ng/mL TGF-b1 for up
to 72 hours to induce myofibroblast differentiation and
treated with either a chemical RhoA inhibitor (Rhosin) or
incubated with dimethyl sulfoxide alone. The effects of
RhoA inhibition on mRNA expression of CCN2, FN1,
MMP2, and COL1A1/COL1A2 (collagen type 1 a chains)
were subsequently assessed using qPCR. The results
demonstrated that RhoA inhibition attenuated CTGF, FN1,
MMP2, COL1A1, and COL1A2 mRNA expression, indi-
cating that RhoA regulates expression of these genes in
myofibroblasts (Figure 7). The effects of HYAL2 knock-
down on these RhoA-regulated genes was then investi-
gated (Figure 8). CTGF mRNA expression was
significantly attenuated upon HYAL2 knockdown at all
timepoints after TGF-b1 stimulation (Figure 8A).
Expression levels of FN1, MMP2, COL1A1, and COL1A2
all demonstrated significant attenuation after HYAL2
knockdown compared to scrambled controls in cells that
had differentiated to myofibroblasts (Figure 8, BeE).
Furthermore, there was no effect on HYAL2 mRNA
(Figure 9A) or HYAL2 protein (Figure 9B) expression
after Rhosin treatment, suggesting that RhoA inhibition
did not directly influence HYAL2 expression.
HYAL2 Regulation of RhoA-Mediated Contractility and
Migration in Myofibroblasts
The activity of Rho GTPases in regulating the polymeriza-
tion and organization of actin and myosin filaments has been
previously established.52 The role of RhoA in regulating
cytoskeletal-related myofibroblast functions was therefore
assessed in our experimental cell systems. The effect of
RhoA on TGF-b1edriven activated fibroblast contractility
was initially assessed. The results demonstrated that TGF-
b1 enhanced collagen type I gel contraction, whereas
treatment with the RhoA inhibitor (Rhosin) abrogated TGF-
b1edriven activated fibroblast contractility (Figure 10A). In
addition, RhoA inhibition also markedly attenuated TGF-
b1edriven migration in these cells (Figure 10B). To
determine the role of HYAL2 in regulating TGF-b1edriven
activated fibroblast contractility and migration, fibroblasts
were transfected with either scrambled siRNA or siHYAL2
and subsequently incubated with 10 ng/mL TGF-b1. Similar
to the effects seen with RhoA inhibition, knockdown of
HYAL2 reduced TGF-b1-driven fibroblast contractility and
significantly suppressed migration, over the course of 24
hours (Figure 11). Thus, RhoA and HYAL2 are both
involved in mediating pathways associated with TGF-
b1edriven activated fibroblast contractility and migration.Discussion
HYAL2 is a 54-kDa protein that has high-level expression in
most tissues, including skin, liver, kidneys, skeleton, heart, and
lungs, suggesting that it has an important biological role.ajp.amjpathol.org - The American Journal of Pathology
HYAL2 Governs RhoA Driven Cell ResponsesHowever, while the primary function of HYAL2 is considered
to be enzymatic, it is only a weak HA-degrading enzyme.
Hence, although recent studies have indicated thatmutations in
HYAL2 lead to significant cardiac, skeletal, hematopoietic,
and other abnormalities,15,16,18,20 the cellular mechanisms
through which HYAL2 achieves its effects and regulates
biology are poorly understood.
The findings from this study, in conjunction with other
recently published studies, indicate that HYAL2 has
important and previously undescribed nonenzymatic effects
that influence distinct and opposing fibroblastic cell func-
tions. Previous studies demonstrated the role of nuclear
HYAL2 as a key regulator of CD44 alternative splicing, and
in particular, highlighted its function in promoting the
expression of an antifibrotic CD44 splice variant termed
CD44v7/8.27,43 Cell-surface expression of this CD44 splice
variant in fibroblasts resulted in prevention and reversal of
TGF-b1edriven myofibroblast differentiation, thereby
limiting profibrotic tissue damage. In contrast, the results
presented here demonstrate that cytoplasmic HYAL2 pro-
motes profibrotic processes. This study shows that TGF-b1
promotes HYAL2 relocalization to the cytoplasm, where it
binds to the actin cytoskeleton. HYAL2 in this context
modulates RhoA signaling, promoting downstream profi-
brotic myofibroblast functions. Specifically, HYAL2 en-
hances RhoA-dependent cell migration and, to a lesser
extent, contractility. Many studies demonstrate RhoA to be
promigratory, while some studies report RhoA to be anti-
migratory.52,55,56 While this dichotomy is not fully under-
stood, the findings from this study indicate that
HYAL2eRhoA interactions are crucial in regulating RhoA-
dependent migration and may explain its divergent func-
tions. HYAL2 also promotes increased collagen, FN, CTGF
(CCN2) and MMP2 expression. In these studies, despite
having low HA catabolic activity, HYAL2 influences wide-
ranging cellular and matrix effects through its influence on
myofibroblast phenotype and function. Given the central
role of myofibroblasts in regulating homeostasis and driving
pathology, the broad expression of HYAL2 in tissues and
the widespread impact of its dysregulation on homeostasis
and disease are now more understandable. Whether HYAL2
has similar nonenzymatic actions in nonstromal cell pop-
ulations remains to be investigated.
HYAL2 requires a pH optimum of 4.0 for its HA-
breakdown activity.22 Little is known regarding the factors
that may govern the switch from enzymatic to nonenzymatic
HYAL2 functions. At the cell surface,
glycosylphosphatidylinositol-linked HYAL2 has been
shown to interact with the Naþ/Hþ exchanger 1.57 Naþ/Hþ
exchanger 1 has been proposed to create acidic microenvi-
ronments at the cell surface accounting for any membrane-
bound HYAL2 catalytic activity. Furthermore, cell-surface
HYAL2 catalytic activity has previously been found to be
dependent on the expression of cell-surface CD44.58 Nu-
clear HYAL2 has been found to be associated with a range
of RNA- and DNA-processing proteins and influences theThe American Journal of Pathology - ajp.amjpathol.orgincorporation of serine- and arginine-rich splice factors and
snRNAs into the spliceosome.27 HYAL2 has also been
identified intracellularly within lysosomes and endosomes
and now binding to the cytoskeleton.43,59 At each of these
cell locations, HYAL2 was identified as having distinct
cellular functions, and it is possible to speculate that the
distinct actions of HYAL2 are influenced by its cellular
localization. It may be that the nonenzymatic functions of
HYAL2 predominate when the protein is localized in a
nonacidic microenvironment and detached from CD44 in
support of findings from previous studies.58 The mecha-
nisms that influence HYAL2 cellular localization are as yet
unknown, and the proteineprotein interactions that may
influence HYAL2 trafficking between the cell surface,
cytoplasm, and nucleus will be the focus of further study.
HYAL2 is identified as having a catalytic domain, an
HA-binding domain, a glycosylphosphatidylinositol-anchor
domain, and an epidermal growth factorelike domain.
However, the other putative functional domains of HYAL2
that may regulate the recently identified nonenzymatic
functions remain undescribed. It is known that HYAL2 is
involved in a number of proteineprotein interactions,
including HYAL2eCD44 coupling, HYAL2eWW
domainecontaining oxidoreductase 1 and HYAL2ecell
migrationeinducing and HA-binding protein in-
teractions.23,24,60 In these studies, HYAL2 interactions with
these particular proteins influence the effects of HYAL2,
subsequently influencing distinct cellular functions. As an
example, HYAL2 interaction with cell migrationeinducing
and HA-binding protein (formerly known as KIAA1199) is
thought to enhance the catalytic activity of HYAL2.60
Hence, it is also possible that as-yeteunidentified proteins
may influence a conformational change in HYAL2 structure
that is crucial for its various nonenzymatic actions. In the
field of fibrosis research, the generation of catalytically
inactive mutants of HYAL2, and an understanding of both
HYAL2 structural biology and the distinct peptide domains
and HYAL2eprotein interactions that could promote anti-
fibrotic versus profibrotic cellular functions, offer an
important area of research.
In this study we demonstrated that while cytoskeletal-
linked HYAL2 did not mediate TGF-b1edriven myofibro-
blast differentiation, it regulated some very important
myofibroblast functions that ultimately influence fibro-
genesis. Migration and contractility are crucial myofibro-
blast functions facilitating scarring.61 Increased generation
of collagens and FNs are hallmarks of fibrotic matrix pro-
duction by myofibroblasts. In addition, numerous studies
have established a link between increased expression of
CTGF (CCN2) and MMP2 in fibrotic disease.53,62 All of
these functions are downstream effects of RhoA signaling,
as indicated in the experiments using the RhoA inhibitor
Rhosin.51,54 Given the observed direct interaction between
HYAL2 and RhoA demonstrated in this study, it appears
that cytoskeletal-linked HYAL2 is involved in the orches-
tration of RhoA signaling and is likely to influence all1253
Midgley et aldownstream RhoA effects. Furthermore, as there seems to
be a basal interaction between HYAL2 and RhoA, even in
resting/unstimulated fibroblasts, it is speculated that after
TGF-b1 stimulation, both HYAL2 and RhoA move together
from the cell membrane to the cytoskeleton, where they can
both associate with and activate MLCK. In conclusion,
HYAL2 in myofibroblasts associates with the actin cyto-
skeleton and interacts with cytoskeletal-associated RhoA,
and this interaction is essential for mediating downstream
profibrotic RhoA-signaling effects.
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